← All trials
NCT03089905
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2017
- Primary completion
- Apr 1, 2022
- Completion date
- Apr 1, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 450
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Murdoch UniversityLead sponsor
- University of New South WalesCollaborator
- University of MelbourneStudy chair
- Oregon Health and Science UniversityCollaborator
- University of TorontoCollaborator
- University of LondonCollaborator
- University of GenevaCollaborator
- University of GroningenCollaborator
- Texas Medical CenterCollaborator
- Starship Children's HealthCollaborator
- Uppsala UniversityCollaborator
- University of MelbourneCollaborator
- University of Western AustraliaCollaborator
- Harvard UniversityCollaborator
- Rush UniversityCollaborator
- Erasmus University RotterdamCollaborator
- University of RochesterCollaborator
- The University of Texas, DallasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.